1-3 of 3
Gregory F Guzauskas, MSPH, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Is Obinutuzumab Plus Chemotherapy Followed By Obinutuzumab Monotherapy for Previously Untreated Follicular Lymphoma Patients Cost-Effective in the US?

Gregory F Guzauskas, MSPH, PhD, Anthony Masaquel, MPH, PhD, Per-Olof Thuresson, MSc, Jia Li, PhD, Carolina M Reyes, PhD, David Veenstra, PharmD, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5603.
https://doi.org/10.1182/blood.V130.Suppl_1.5603.5603
Published: 2017
Journal Articles

What Is the Cost-Effectiveness of Obinutuzumab Plus Bendamustine Followed By Obinutuzumab Monotherapy for the Treatment of Follicular Lymphoma Patients Who Relapse after or Are Refractory to a Rituximab-Containing Regimen in the US?

Gregory F. Guzauskas, MSPH, PhD, Anthony Masaquel, MPH, PhD, Carolina Reyes, PhD, Kenneth Wilhelm, MD, Tania Krivasi, MSc, David L. Veenstra, PharmD, PhD
Journal: Blood
Blood (2016) 128 (22): 3605.
https://doi.org/10.1182/blood.V128.22.3605.3605
Published: 2016
Journal Articles

Risk-Benefit Trade-Off of Pediatric-Inspired Versus Hyper-CVAD Protocols for Philadelphia Negative Acute Lymphocytic Leukemia (ALL) in Adolescents and Young Adults: A Modeling Analysis

Gregory F. Guzauskas, MSPH, PhD, Kathleen F. Villa, MS, Trudy F. Vanhove, MD PhD MBA, David L. Veenstra, PharmD, PhD
Journal: Blood
Blood (2014) 124 (21): 1281.
https://doi.org/10.1182/blood.V124.21.1281.1281
Published: 2014